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Ormond Street Hospital for Children NHS, London, UK
Under normal physiological conditions, pancreatic β-cells secrete insulin to maintain 
fasting blood glucose levels in the range 3.5–5.5 mmol/L. In hyperinsulinemic hypoglyce-
mia (HH), this precise regulation of insulin secretion is perturbed so that insulin continues 
to be secreted in the presence of hypoglycemia. HH may be due to genetic causes 
(congenital) or secondary to certain risk factors. The molecular mechanisms leading to 
HH involve defects in the key genes regulating insulin secretion from the β-cells. At this 
moment, in time genetic abnormalities in nine genes (ABCC8, KCNJ11, GCK, SCHAD, 
GLUD1, SLC16A1, HNF1A, HNF4A, and UCP2) have been described that lead to the 
congenital forms of HH. Perinatal stress, intrauterine growth retardation, maternal diabe-
tes mellitus, and a large number of developmental syndromes are also associated with 
HH in the neonatal period. In older children and adult’s insulinoma, non-insulinoma pan-
creatogenous hypoglycemia syndrome and post bariatric surgery are recognized causes 
of HH. This review article will focus mainly on describing the molecular mechanisms that 
lead to unregulated insulin secretion.
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iNTRODUCTiON
Hyperinsulinemic hypoglycemia (HH) is biochemically characterized by the unregulated 
secretion of insulin from the pancreatic β-cells in the presence of low blood glucose levels. 
Under normal physiological conditions, β-cells synthesize, store, and secrete insulin in a pre-
cisely controlled manner so that the fasting blood glucose level is kept within a narrow range of 
3.5–5.5 mmol/L (1).
The unregulated insulin secretion promotes glucose uptake into the skeletal muscles, liver, and 
adipose tissue, exacerbating the hypoglycemia further. Simultaneously, glucose production (via 
gluconeogenesis and glycogenolysis), lipolysis, and ketogenesis are all inhibited. In addition to the 
actions of insulin in inhibiting glucose production, there are also defects in the glucose counter 
regulatory hormones such as cortisol and glucagon (2–4). The lack of glucose (the brains primary 
source of fuel) accompanied by the deprivation of alternative substrates in the form of ketone bodies 
and lactate increase the risk of brain damage in these patients (5).
The genetic mechanisms that lead to HH involve defects in the key pathways regulating insulin 
secretion from pancreatic β-cells. These genetic defects perturb the normal physiological mecha-
nisms of glucose-regulated insulin secretion, leading to inappropriate and unregulated insulin 
secretion. The unregulated insulin secretion leads to severe hypoglycaemia. The gene defects, 
TABLe 1 | An outline of different causes of HH.
Genetic causes of HH
1. ABCC8
2. KCNJ11
3. GCK
4. SCHAD
5. GLUD1
6. SLC16A1
7. HNF1A
8. HNF4A
9. UCP2
Secondary causes of HH (transient)
1. Maternal diabetes mellitus (gestational and insulin dependent)
2. Intrauterine growth restriction
3. Perinatal asphyxia
4. Rhesus isoimmunization
Metabolic causes of HH
1. Congenital disorders of glycosylation
2. Tyrosinaemia type 1
Syndromic causes of HH
1. Beckwith–Wiedemann
2. Kabuki
3. Trisomy 13
4. Central hypoventilation syndrome
5. Leprechaunism (insulin resistance syndrome)
6. Mosaic Turner
7. Sotos
8. Usher
9. Timothy
10. Costello
Miscellaneous causes of HH
1. Postprandial HH
a. Insulin gene receptor mutation
b. Dumping syndrome
c. Non-insulinoma pancreatogenous hypoglycemia syndrome
d. Insulin autoimmune syndrome
e. Bariatric surgery
f. Insulinoma
2. Non-islet cell tumor hypoglycemia
3. Factitious hypoglycemia
4. Drug induced
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which lead to congenital HH can be broadly categorised into 
two groups, channelopathies and metabolopathies.
The most severe forms of HH occur in the neonatal period 
(however, it can also present in the infancy, childhood, and in 
adults) and are usually congenital HH (CHH). HH may also occur 
due to secondary causes and these are summarized in Table 1 (6). 
The genetic causes of CHH are listed in Table 1.
The most severe forms of CHH are due to defects in the genes 
(ABCC8 and KCNJ11), which encode for the sulfonylurea recep-
tor protein (SUR1) and inwardly rectifying potassium channels 
(Kir6.2) proteins, respectively, of the potassium sensitive KATP 
channel (7, 8). These defects are referred to as channelopathies 
(9). The coassembly of four SUR1 and four Kir6.2 subunits forms 
a single ATP-sensitive potassium channels (KATP) (Figure 1). The 
second category, metabolopathies, constitutes the majority of the 
other genes known to cause CHH.
In this review, we first review in detail the molecular basis of 
the ATP sensitive potassium KATP channel function, and then 
outline the molecular pathways that lead to CHH due to defects 
in these channels and second we describe the biochemical causes 
of HH due to defects in the non-KATP channel genes.
Channelopathies: Background to  
ABC Proteins
The transportation of ions, molecules, and various other 
proteins across a membrane is of paramount importance to 
the functioning of all living cells. A simple example is of the 
E. coli cell which transports ~106 glucose molecules per second 
into the cell in order to meet its physiological requirements 
(10). The movement of these essential (and non-essential) 
molecules is mediated by membrane-bound transporter 
proteins. There are 48 ATP-binding cassette (ABC) transport-
ers present in humans (11). In the human genome, there are 
seven sub-groups of the ABC transporter family, involved in a 
diverse range of functions. This includes multidrug resistance, 
cholesterol and lipid transport, mitochondrial iron homeosta-
sis, and also the ATP-dependent regulation of ion channels, 
which include the cystic fibrosis transmembrane conductance 
regulator and the sulfonylurea urea receptor. Many disease 
phenotypes arise as a result of mutations in the ABC genes, 
such as cystic fibrosis, diabetes, and CHH (12). The ABCC8 
gene stands for ATP-Binding Cassette, Sub-Family C, Member 
8, and it codes for the SUR1 protein, which is a major example 
of an ABC protein.
All ABC proteins including SUR1 harbor two major domains, 
which consists of the transmembrane domains (TMD) and the 
nucleotide-binding domains (NBD). The TMD, situated in the 
cell membrane, is primarily composed of α-cell-helices. The 
NBD’s, however, are always found within the cytoplasm of the 
cell. A distinguishing feature of ABC proteins is the presence of 
highly conserved sequence motifs, such as the Walker A (WA) and 
Walker B (WB) motif. The former is a characteristic phosphate-
binding loop, and the latter is Magnesium [Mg2+-binding site 
(13)]. Another striking feature is the Q-loop, which is positioned 
in between the WA and WB motif, known to associate with the 
gamma phosphate through a water bond. These three motifs 
combine together to form the NBD.
Other characteristic feature of ABC proteins is the “switch” 
region, which contains a histidine loop (H-Loop). It has been 
hypothesized that it polarizes the water molecule for hydrolysis. 
In ABC proteins, the variation arises within the TMD’s, which 
can vary among the different ABC proteins. This provides the 
membrane protein with its ability to sense changes in different 
nucleotides or other ions and compounds (12).
The ABCC8 Gene
The ABCC8 gene is located within the human genome on 
chromosome 11p15.1. This gene has 39 exons (14), translating 
into either a 1581 or 1582 amino acid protein (15), which has a 
molecular weight of 176.9 kDa (16). The three transmembrane 
domains in SUR1 are TMD0, TMD1, and TMD2 (17). There 
are also two cytosolic nucleotide-binding domains (NBD1 and 
NBD2) within a single SUR1 transmembrane protein. SUR1 can 
combine ATP hydrolysis to transport substrates, however within 
FiGURe 1 | KATP channel structure on β-cell membrane. (A) The SUR1 subunit is made up of three transmembrane domains (TMD0, TMD1, and TMD2) and 
two nucleotide-binding domains (NBD1/NBD2), which face the cytoplasm. The NBD’s harbor the Walker A (WA) and Walker B (WB) motifs. Kir6.2 is the pore-forming 
subunit, containing two membrane-spanning domains, connected by an extracellular pore-forming region and cytoplasmic –NH2 and –COOH terminal domains.  
(B) Illustration of the predicted octameric structure of KATP channels, comprising four Kir6.2 and four SUR1 proteins.
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the KATP channel complex it is primarily role is not to transport 
substrates; instead it regulates the activity of the Kir6.2 subunit. 
SUR1 also confers the KATP channel with its sensitivity and 
response to sulfonylureas such as glibenclamide (18) and chan-
nel activators such a diazoxide, which is commonly used to treat 
medically responsive CHH (19).
SUR1: The walker A, walker B, and 
Nucleotide-Binding Domain
The WA and WB motifs contain the consensus sequence for 
nucleotide hydrolysis, making them one of the most prominent 
features of SUR1 proteins (20). A flexible loop structure is formed 
at the WA motif, which contains the sequence Gly–X–Gly–X–Gly. 
This is followed by a lysine residue, which is predicted to bind to 
the α-cell-phosphate of ATP. A hydrophobic β sheet is formed at 
the WB motif, which has an adjacent aspartic acid residue, and 
this has been postulated to interact with the Mg2+ ion of MgATP 
(13). It has been predicted that the WA and WB motifs in KATP 
channels are able to interact with the phosphoryl group, and then 
co-ordinate the Mg2+ in the MgATP complex (21). There is a 
third motif, which situated in between the WA and WB, and this 
region has been denoted as a “linker,” which transduces the effect 
of nucleotide binding and hydrolysis (22).
The WA and WB sequence motif is contained in both NBD1 
and NBD2 of SUR1 (20), and this motif can sense the levels 
of intracellular nucleotides within pancreatic β-cells. The key 
nucleotide is ATP, which is produced in large quantities after a 
meal when cell metabolism is high. ATP has an inhibitory effect 
on KATP channels, although MgATP can have the opposite effect. 
The hydrolysis of MgATP is believed to involve a conformational 
change at the NBD’s, which in turn generates two nucleotide 
binding sites known an ATP-binding site 1 (ABS1) and 2 (ABS2), 
believed to mediate the hydrolysis of MgATP. Azido-ATP label-
ling experiments demonstrate that the binding of nucleotides to 
NBD2 stabilizes the binding of ATP to NBD1 (23). It has been 
shown that NBD1 and NBD2 can be coimmunoprecipitated 
(24). A soluble NBD1–GFP construct can be taken to the cell 
membrane by TMD2–NBD2 construct when they co-expressed 
in insect cells (25).
The KCNJ11 Gene
In the vertebrate genome, there are two genes coding for Kir pro-
teins, this includes the KCNJ8 and KCNJ11 genes which encode 
for the Kir6.1 and Kir6.2 proteins, respectively. The KCNJ11 gene 
is also located on chromosome 11p15.1. However, in contrast to 
the ABCC8 gene, the KCNJ11 gene only contains 1 exon, which 
translates into a 390 amino acid protein with a molecular weight 
of 43.5 kDa (14). A distinctive feature of Kir proteins is that they 
enable positive current to flow inwards into the cell, despite there 
being equal concentrations of K+ ions either side of the mem-
brane. Kir6.2, however, has its own unique properties, the first 
being that it is not a strong inward rectifier (26); nevertheless its 
origins are also from a large super-family of Kir proteins, namely 
Kir1–Kir7 (27, 28). In the KATP channel complex, the Kir6.2 proteins 
functions as the pore of the channel, allowing K+ ions to flow 
through. Kir6.2 is composed of two transmembrane domains, 
which are linked by an extracellular pore-forming region. The 
–NH2 and –COOH terminal domains are located within the 
cytoplasmic side of the protein.
HiSTOLOGiCAL CHARACTeRiZATiON  
OF CHH
Three histological forms of CHH currently exist; focal CHH, 
diffuse CHH, and atypical CHH. Focal CHH is characterized by 
pathological pancreatic β-cells localizing to one or more specific 
locations in the pancreas. In contrast, in diffuse CHH, there 
are abnormal islet cells throughout the pancreatic tissue (29, 
30). Although clinical presentation of both these types of CHH 
appears to be similar, their molecular mechanisms are different.
FiGURe 2 | Nucleotide regulation of KATP channels. The channel is 
activated by the presence of PIP2 and the conversion of MgATP to MgADP. 
High concentrations of ATP block the pore and cause channel closure.
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Atypical CHH are usually described as cases that are histologi-
cally difficult to categorize and are on general due to morphologi-
cal mosaicism in a portion of the pancreas.
Focal CHH
The focal lesion has abnormal islet cells, whereas the surround-
ing pancreatic areas seem histologically normal, but islets are 
reported to have small nuclei. The non-focal area islet cells have 
a reduction in cytoplasmic mass as well as diminished proinsulin 
production (30–33).
Focal CHH appears to be a result of two events; (1) a pater-
nally inherited KATP channel mutation and (2) the loss of the 
 corresponding maternal allele located within the focal area. This 
results in an imbalance in the expression of various imprinted 
genes. These include the expression of insulin-like growth 
 factor  2 (IGF-2) (34) and tumor suppressor genes H19 and 
cyclin-dependent kinase inhibitor 1C (CDKN1C). These genes 
have been shown to promote β-cell hyperplasia and are expressed 
paternally and maternally, respectively.
In a few cases, paternal allele duplication of chromosome 11 
has also reported to cause focal CHH (35). However, the majority 
of focal CHH due to heterozygous paternally inherited mutation 
in the ABCC8 or KCNJ11 gene account for almost 30–40% of all 
CHH cases (36). The imbalanced 11p15 region interrupts pancre-
atic β-cell gene expression, which leads to focal islet hyperplasia.
Focal CHH is usually confirmed by a fluorine-18 dihydroxy-
phenylalanine-positron emission tomography (18F-DOPA-PET) 
scanning. This scan can identify the location of one or more focal 
lesions with diagnostic accuracy (37). Surgical resection of the 
lesion usually resolves HH.
Diffuse CHH
The diffuse pancreas affects all the pancreatic β-cells, but islet 
morphology is preserved (32). Affected islets cells appear with 
large hyperchromatic nuclei and an abundant mass of cytoplasm 
(29–33). Patients with diffuse CHH either have a homozygous 
recessive or a compound heterozygous mutation in their KATP 
channel genes. This form of CHH accounts for 60–70% of all CHH 
cases. Patients are mainly medically unresponsive, and hence, 
require a “near total pancreatectomy.” However, this often leads 
to patients having life-long diabetes and exocrine insufficiency.
Atypical CHH
Histologically, atypical CHH are categorized when the pancreatic 
morphology neither fits the focal nor diffuse CHH category (34, 
38). The islets have been described to be enlarged or shrunken, 
and atypical CHH still remains poorly defined. Variability in 
management of atypical CHH occurs because some cases have 
been cured with a surgical resection while others also required 
medical therapy. 18F-DOPA-PET scanning usually used to 
recognize between focal and diffuse CHH has failed to identify 
atypical CHH (34).
To date, no associated mutations have been reported for 
atypical CHH, with the exception of one patient with an ABCC8 
nonsense mutation (p.Gln54X) (38). Other studies have described 
the heterogeneous expression of hexokinase 1 of the pancreatic 
β-cells in atypical pathology (39, 40). Furthermore, a recent study 
has also implicated an abnormal postprandial incretin response 
in two cases of atypical CHH of unknown genetic cause (40).
KATP CHANNeLS AND iNSULiN 
SeCReTiON
In 1983, Noma and colleagues identified K+ currents from tissue 
extracted from heart muscle cells, when they were induced with 
metabolic poisons or under hypoxic conditions (41). During the 
period of 1983–1988, there was a vast amount of research done 
on understanding the basic electrophysiological properties of 
KATP channels. As a result, the expression of KATP channels has 
been observed in many tissues, including cardiac muscle, skeletal 
muscle, smooth muscle, pancreatic β-cells, and neurons (41–45). 
KATP channel currents have now also been identified in the rough 
endoplasmic reticulum of rat hepatocytes (46).
However, it was not until the mid-1990s that recombinant 
in vitro functional work had advanced in the field of KATP channels. 
It was soon realized that the lone expression of Kir proteins was 
not enough to generate KATP channel currents in cells. This lead 
to the discovery of the SUR protein and the functional reconstitu-
tion of KATP channels (14). The coexpression of the proteins leads 
to the channel being sensitive to nucleotides and sulfonylureas.
Several studies carried out in isolated pancreatic β-cells have 
shown the functional significance of KATP channels as they play a 
major role in glucose homeostasis. These studies have used elec-
trophysiological and radioactive techniques to elucidate the effect 
of sulfonylureas, potassium channel openers, and nucleotides on 
pancreatic β-cells (47–52).
The key regulators of KATP channels are intracellular nucleo-
tides such as ATP and ADP (Figure  2). This has a direct link 
to cellular metabolism as the production and consumption of 
ATP has a direct impact on the activity of KATP channels. A rise 
in the intracellular concentration of ATP changes the physical 
conformation of KATP channels from an open to a closed state. 
The closure of KATP channels in the β-cell membrane changes the 
resting membrane potential (−70 mV) from being hyperpolar-
ized to being depolarized (−50 mV), which in turn triggers the 
5Nessa et al. Hyperinsulinemic Hypoglycemia
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activation of voltage-gated calcium channels (53). The influx of 
Ca2+ ions into the β-cell enhances the exocytosis of insulin, which 
ultimately aims to restore blood glucose levels (54).
Gating Mechanisms in KATP Channels
The gating properties of KATP channels are affected by many differ-
ent ligands. ATP has the ability to block the channel both in the 
presence and absence of Mg2+ ions, whereas PIP2 can activate the 
channel (Figure 2) (55–57). It has been suggested that there may 
be two gates in the permeation pathway. It has been observed that 
there is in fact ligand-independent gating, which indicates that 
the gate may be in the selectivity filter. Experimental observations 
suggest that KATP channels may harbor two independent types of 
gates in the permeation pathway (58). This includes:
 (1)  Ligand independent: fast gating, controlled by changes in 
membrane potential, this suggests that there is a selectivity 
filter, something which allows K+ through irrespective of all 
metabolic changes.
 (2)  Ligand dependent: slow gating, modulated by membrane 
PIP2 and nucleotides.
Experiments studying the kinetics of KATP channels reveal that 
un-liganded subunits are quite unstable. This means that subu-
nits, which are not bound by either ATP or PIP2, are unstable, but 
once bound, they are mutually excluded. Hence, the subunits will 
be bound by one ligand or another at any one time.
Wild type (WT) KATP channel subunits are bound to PIP2 in 
the absence of ATP, which is why the channels are in the open 
state around ~90% of the time (59). But for the channel to be 
active, all four subunits must be in the open state. However, 
binding of ATP to the un-liganded subunit will trap it into the 
closed state. In WT subunits, the association constant for ATP 
is around ~10 μM. In energized cells, the concentration of ATP 
is two to three magnitudes higher; therefore, it is likely that each 
WT subunit is bound by ATP around ~90% of the time. Locking 
any one subunit in the closed conformation is enough to induce 
channel closure (60, 61). So apart from extreme conditions, the 
probability of the channel being in the open state is <0.14, which 
means that without the stimulatory effects of Mg2+ nucleotides 
the channel will almost always remain closed. PIP2 has the effect 
of “pulling” the channels to open, whereas ATP does the opposite 
and tries to “push” the channels to close.
Previous studies have shown that ATP destabilizes the channel 
open state and overall it enhances channel closure (62–65). In 
earlier studies, it was understood that the interaction of one ATP 
molecule with the open state resulted in channel closure. However, 
there are four Kir6.2 subunits in every KATP channel complex, 
therefore there are four ATP inhibitory binding sites and so up 
to four ATP molecules can bind to the open state. The binding of 
four ATP molecules can either work together in concert to induce 
channel closure or they can act independently (66). To this date, the 
relationship between the number of ATP molecules bound and the 
closure of the Kir6.2 pore is not well understood. Hence, it is debat-
able on whether the KATP channel, which is an octameric complex, 
acts under a concerted gating mechanism using all four subunits, 
or whether there are transitional steps involving each subunit.
Nucleotide Regulation of KATP Channels
The changing concentrations of ATP, ADP, GTP, and GDP 
regulate the opening and closing of the KATP channels. Adenine 
nucleotides, such as ATP and ADP, are able to interact with Mg2+ 
ions in a stimulatory manner; however, in the absence of Mg2+ 
ions, the non-hydrolytic binding of ATP takes precedence over 
KATP channels and promotes channel closure. Mg2+ ions are one 
of the most vital elements in the human body; hence, they are 
present at all times inside cells (67). Therefore, in order for the 
KATP channels to close, there must be significantly higher levels 
of ATP than MgADP.
MgADP can stimulate channel activity by direct binding, or 
by the binding and hydrolysis of MgATP (68). This can be seen 
in Figure  2. ATP binds to the cytosolic domain of Kir6.2. In a 
study by Craig et al. (66), they examined the mechanism of inhibi-
tion by ATP, and they achieved this by removing Mg2+ from the 
solutions, which enables them to study ATP interactions in isola-
tion from nucleotides (66). The single channel kinetics of KATP 
channels show bursts of short openings and closings, which are 
separated by long, non-conducting interbursts intervals. Once 
ATP is added however, it causes a notable reduction in bursts 
duration, and a significantly longer duration of the closed states. 
Hence, ATP interacts with all these states, and ATP ends the burst 
state and aids the start of the long closed state.
Until 1997, it was widely accepted that the prime location for 
ATP inhibition was on the SUR1 subunit of the KATP channel com-
plex, possibly within the NBD’s (69). However, the discovery that 
a truncated Kir6.2 protein could produce a homomeric channel 
(70), and function similar to a KATP channel, made it clear that the 
ATP inhibition actually affected the Kir6.2 subunit.
KATP Channel Mutations Causing HH
Inactivating mutations in any region of the ABCC8 and KCNJ11 
genes account for the vast majority of mutations known to date. 
Mutations in these genes cause the most severe form of CHH 
that is typically medically unresponsive to therapy with diazox-
ide. The condition presents in the neonatal period with severe 
hypoglycemia, which is difficult to control with oral feeds and 
will require the infusion of concentrated intravenous dextrose. 
Both recessive and dominant mutations can have a major nega-
tive impact on many aspects of KATP channel function, regulation, 
and processing. Ultimately, this leads to persistent depolarization 
of the pancreatic β-cell membrane, which leads to unregulated 
insulin secretion (71). A recessive mutation observed in >90% 
of Ashkenazi Jewish population is p.Phe1388del (ABCC8) (9), 
which is known to cause severe CHH (14, 15). The p.Val187Asp 
and p.Glu1506Lys mutations in ABCC8 are largely found in the 
Finnish populations, which are also known to cause CHH. A 
schematic representation of known mechanisms of KATP channel 
defects has been shown in Figure 3. This section will describe 
some of these known mechanisms.
Mechanism 1: Recessive KATP Channel 
Mutations
The membrane expression of KATP channels is vital to its role 
in maintaining the resting membrane potential of pancreatic 
FiGURe 3 | illustration of KATP channel protein production and 
regulation. (A) Normal production of KATP channels involves transcription of 
ABCC8 and KCNJ11 to produce pre-mRNA, this undergoes modification to 
become mature mRNA. The mRNA exits the nucleus and is translated into a 
protein on ribosomes embedded on the ER. The polypeptide(s) fold into the 
tertiary structure and enter the Golgi apparatus for post-translational 
modifications. Vesicles containing the fully assembled KATP channel proteins 
are then expressed at the membrane. (B) Mechanisms of CHI include defects 
in regulation, biogenesis, and trafficking. In these cases, the defective KATP 
channel may undergo protein degradation in lysosomes.
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β-cells and insulin secretion. In order for KATP channels to traffic 
to the plasma membrane, the SUR1 and Kir6.2 subunits must 
first assemble into their tertiary protein structure. This allows 
the endoplasmic reticulum retention signal known as RKR 
(Arg–Lys–Arg) present in both subunits to be shielded, enabling 
successful migration of the KATP channel complex from the 
endoplasmic reticulum to the plasma membrane (Figure 3) (72, 
73). The following ABCC8 mutations cause trafficking defects 
including: p.Arg1437Gln, p.Phe1388del, p.Arg1394His, and 
p.Leu1544Pro. The KCNJ11 mutation p.His259Arg produces a 
non-functional KATP channel with impaired trafficking to the cell 
surface.
Within the SUR1 subunit, the RKR signal is located on the 
N-terminal of NBD2, and in Kir6.2, it is on the C-terminal. 
Removal of the last 36 amino acid residues in Kir6.2, which 
contains the RKR signal results in the membrane expression of 
a homotetrameric Kir6.2 structure, which has unique properties 
unlike that of KATP channels (70). There are prominent differences 
between WT KATP channels and homotetrameric Kir6.2 channels. 
For example, the half-maximal inhibition concentration (IC50) 
by ATP is ~10-fold higher in homotetrameric Kir6.2 channels 
compared to WT channels.
The SUR1 and Kir6.2 subunits of the KATP channel complex 
are sensitive to stimulation via Mg2+ bound nucleotides (MgATP, 
MgADP). A key function of the SUR1 subunit is to regulate the 
conductance of the Kir6.2 protein within the channel complex. 
Recessive mutations have been shown to affect the conductance 
of the KATP channel, and this includes the ABCC8 mutations 
p.Thr1139Met and p.Arg1215Glu (74). These mutants display a 
loss of ADP-dependent gating, which causes constitutive inhi-
bition of KATP channels by ATP. The p.Arg1420Cys is another 
ABCC8 mutation, which generates a KATP channel that has a 
fivefold reduced affinity for ATP and ADP (75). In addition, the 
ability of MgATP and MgADP to stabilize ATP binding at NBD1 
is also affected. The p.Arg1420Cys mutation acts as a hindrance 
to the transduction of a conformational change at NBD2 and 
thereby its ability to stabilize ATP binding at NBD1.
Mechanism 2: Dominant Mutations in 
ABCC8 and KCNJ11
The p.Glu1506Lys mutation was the first dominant mutation 
identified in the ABCC8 gene, which caused CHH in seven 
related patients (76). The diagnosis was based on the presence of 
inappropriately high levels of insulin, non-ketotic hypoglycemia, 
and a raised demand for glucose in order to prevent hypoglyce-
mia. Mutations in the KCNJ11 gene causing diazoxide responsive 
CHH have also been reported. Patients with a dominant mutation 
in ABCC8 or KCNJ11 have a milder form of CHH and are mostly 
responsive to medical therapy (77), thus avoiding a pancreatec-
tomy. The age of presentation is usually later than those with 
the recessive condition. Dominant mutations in ABCC8 and 
KCNJ11 demonstrate normal assembly with their respective 
WT partner and normal trafficking of assembled channels to the 
plasma membrane (78). However, dominant mutations causing 
diazoxide unresponsive CHH can generate KATP channels, which 
are retained in the endoplasmic reticulum.
Functional Consequences of Dominant 
Diazoxide Responsive CHH
Thornton et  al. (79) identified a novel tri-nucleotide deletion 
in the ABCC8 gene, which caused the loss of serine 1387 (79). 
Experiments were conducted in COSm6 cells using human 
Kir6.2 and SUR1, which were transfected by electroporation. The 
rubidium (Rb86+) flux assay using metabolic inhibitors (2-deoxy 
glucose and oligomycin) and diazoxide revealed that when 
the p.Ser1387del mutation was expressed alone, it showed no 
7Nessa et al. Hyperinsulinemic Hypoglycemia
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response to metabolic inhibitors, or even to lower ATP concen-
trations, hence the mutation was disease causing. However, when 
the p.Ser1387del was expressed with WT SUR1, it generated the 
same level of activation as the pure WT channels. This is in con-
trast to the p.Glu1506Lys mutation, which only exhibited partial 
response to channel activators when expressed with WT SUR1 
(76). The p.Ser1387del mutant, however, does reach the plasma 
membrane. Hence, the cause of CHH may be due to the lack of 
active KATP channels at the membrane.
Dominant Mutation Carriers  
Developing Diabetes
A striking feature of dominant mutations is that dominant muta-
tions carriers have the tendency to develop diabetes later in life 
(76). This was the case with five mothers of CHH patients who 
had developed gestational diabetes, and two of them experienced 
hypoglycemia during infancy. The proposed theory suggests that 
β-cell apoptosis, may be what is causing diabetes later in life (80). 
It has been claimed that as CHH is linked with β-cell depolariza-
tion, enhanced Ca2+ entry into the cell and overall increase in 
intracellular Ca2+ concentrations, then ultimately this increased 
energy demand required to transport the additional Ca2+ into 
the cell may be contributing to β-cell apoptosis. Therefore, the 
use of diazoxide may relieve the cell and delay the onset of β-cell 
apoptosis, and hinder the development of diabetes, as diazoxide 
reduces the influx of Ca2+.
However, there is controversy as to whether the dominant 
mutations predispose to diabetes later in life (79). Two large 
cohorts of dominant mutation carriers in different centers have 
shown opposing results (76, 78). Huopio et al. (76) saw that six 
out of eight mothers developed impaired glucose tolerance dur-
ing pregnancy. However, Pinney et al. (78) had a larger group and 
did not see a positive trend toward diabetes in mutation carries. 
Only 3 out of 13 women had gestational diabetes. It has been 
argued that Sur1 KO mice or Kir6.2 KO mice do not demonstrate 
β-cell apoptosis or develop diabetes (78). And so there are clearly 
other pathways, which act to maintain insulin secretion indepen-
dently of KATP channels. Therefore, the glucose intolerance in both 
dominant and recessive mutations is the result of defective KATP 
channels, and not a sign of developing diabetes in the future (78).
Kapoor et al. (81), however, showed that the main phenotype 
linked with dominant ABCC8 and KCNJ11 mutations is quite 
varied (81). It ranges from asymptomatic macrosomia to persis-
tent HH in childhood. For adults who are mutation carriers, these 
mutations may be a potential cause of dominantly inherited early 
onset diabetes mellitus.
electrophysiology of KATP Channels in CHH
Studies involving the patch-clamp technique have shown that 
there are very few or almost no KATP channels on the surface on 
pancreatic β-cells from patients with diffuse, medically unre-
sponsive CHH (71). The β-cells are depolarized, with variably 
high levels of intracellular Ca2+ in the presence of low glucose 
concentrations. The mutated KATP channels also exhibit no change 
in Ca2+ concentrations upon application of high glucose concen-
trations, tolbutamide, or diazoxide (82).
Diazoxide enhances insulin Secretion via 
Unknown Mechanism
The collection of diseased pancreatic tissue from CHH patients 
who undergo surgery is a complicated process. The subsequent 
study of such tissue is made more problematic due to the challeng-
ing prospect of collecting healthy control tissue. Henquin et al. 
(82) collected suitable controls for comparison studies, and they 
have shown that diazoxide often caused an unexpected increase 
in insulin secretion (82). The results could not be considered as 
an artifact as pinacidil, which is also another KATP channel opener, 
was also reported to have increased the secretion of insulin. It 
is known that higher concentrations of diazoxide reduce the 
production of ATP by affecting the mitochondrial membrane 
potential, but this does not explain why more insulin is released 
from focal and diffuse tissue as less ATP should in fact decrease 
the secretion of insulin.
Correction of Defective KATP Channels in 
Diseased Pancreatic Tissue
Powell and colleagues performed studies on pancreatic tissue 
obtained from CHH patients who underwent a pancreatectomy, 
and demonstrated the rescue of KATP channels (83). Inside-out 
patch-clamp recordings revealed that defective KATP channels 
had a normal response to diazoxide and ADP, when incubated 
at 25°C for 16 h. Whereas at 37°C, the defective KATP channels 
only showed between 0 and 10% activity compared to control 
cells. This work was based on the ABCC7 gene, which encodes 
the cystic fibrosis transmembrane regulator (CFTR), where much 
research has been done to enhance the trafficking of CFTR to the 
cell membrane. This research may now be an invaluable tool to 
enhance the treatment of CHH, by rescuing the defective KATP 
channels (83).
MeTABOLOPATHieS
Metabolopathies is a term used to describe metabolic defects in 
seven genes (GCK, SCHAD, GLUD1, SLC16A1, HNF1A, HNF4A, 
and UCP2), which cause rare forms of CHH (84, 85). These 
genetic defects will be reviewed in this section.
GLUD1: Glutamate Dehydrogenase-1
The GLUD1 gene encodes for the glutamate dehydrogenase-1 
(GDH) enzyme, which is expressed in the mitochondrial matrix. 
Amino acids are an essential source of fuel, which can be used as 
substitutes for glucose to generate ATP. The amino acid glutamate 
is interchangeably converted to α-ketoglutarate by the GDH 
enzyme, which is channeled into the Krebs cycle to generate ATP. 
The rising concentration of ATP triggers the depolarization of 
pancreatic β-cells through the closure of KATP channels, which 
culminates in the secretion of insulin.
The GDH enzyme is known to harbor two structural features, 
which are known to regulate its function. The first is the binding 
of leucine to the enzyme active site, and the second is an allosteric 
inhibitory binding site know to associate with nucleotides such as 
ATP and GTP (86). Dominantly inherited and de novo mutations 
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in the GLUD1 are known to cause CHH. The majority of muta-
tions have been identified in exon 11 and 12 of the GLUD1 gene 
(87); although, there are also reports of mutations in exon 6 and 
7 (88). These activating mutations in the GLUD1 gene desensitize 
the GDH enzyme to inhibition through ATP and GTP (89), caus-
ing re-current activation through the amino acid leucine. This 
leads to the oxidation of glutamate to α-ketoglutarate, which 
triggers an increase in the ratio of ATP/ADP, which subsequently 
enhances the secretion of insulin.
A striking feature of GLUD1–CHH patients is their sensitivity 
to protein, in particular to the amino acid leucine, as it has been 
noted that they can develop re-current symptomatic hypoglyce-
mia after consuming a protein rich meal. Hence, GLUD1–CHH 
is also known as Hyperinsulinism-hyperammonemia syndrome 
(HI/HA). The HI/HA may due to renal ammoniagenesis (90). 
GLUD1–CHH patients present with high levels (two to three 
times the normal) of plasma ammonia; however, they do not 
develop the symptoms associated with hyperammonemia. These 
patients do, however, experience episodes of epilepsy, which sug-
gests that this condition may directly affect the brain. The overall 
medical management of the disease relies on the use of the drug 
diazoxide, which is effective for GLUD1–CHH patients.
GCK: Glucokinase (Hexokinase-4)
The enzyme, glucokinase, plays a fundamental role in “sens-
ing” glucose in cells (91, 92). In pancreatic β-cells, the uptake 
of glucose occurs through an islet-specific glucose transporter, 
which is encoded by the GLUT2 gene. Glucose enters the cell 
through glucose transporters embedded in cell membranes. 
Once inside the cell, a single molecule of glucose is chemically 
modified using the enzyme glucokinase, which phosphorylates it 
and converts it to glucose-6-phosphate. This in essence “traps” the 
glucose molecule inside the cell, and it can no longer exit the cell 
membrane. This enzyme provides a mechanism by which cells are 
able to store glucose and reduce the amount of glucose which is 
circulating in the bloodstream.
Dominant mutations in the GCK gene alter the enzyme’s 
affinity for glucose. The penultimate effect is on insulin secretion, 
which becomes unregulated due to the increasing concentration 
of glucose inside the β-cells. Thus dominant gain-of-function 
mutations in GCK cause CHH (93). A total of 15 mutations have 
been identified in this gene associated with CHH, which target 
various sites across the GCK gene (94). There are many other 
mutations associated with MODY2.
Patients presenting with GCK–CHH can have a variable 
phenotype to one another, as everything from the birth weight to 
the age of presentation to the severity of the disease is dissimilar 
(78). Although there are cases of patients responding to drugs 
such as diazoxide, others have required surgery to control the 
hypoglycemia.
HADH: Short Chain L3-Hydroxyacyl-CoA 
Dehydrogenase
The oxidation of fatty acids and amino acids generates an alterna-
tive source of fuel that can be used to generate ATP. This is an 
essential process, which is highly used during fasting periods 
when the body is deprived of energy in form of dietary carbo-
hydrates. The HADH gene is located on chromosome 4q22-26, 
and it codes for the enzyme Short chain L3-Hydroxyacyl-CoA 
dehydrogenase (SCHAD), which is involved in β-oxidation. This 
enzyme is expressed in many tissues, with high concentrations in 
the islet of Langerhans (95). However, its prime activity is spe-
cifically in the mitochondria, where it catalyzes the oxidation of 
different sized L3-hydroxacyl-CoA to their respective 3-ketoacyl-
CoAs. The reaction requires the use of one NAD+ cofactor, and 
generates a single NADH as a product.
Autosomal recessive mutations in HADH are a rare cause of 
CHH (96), which leads to a reduction in the levels of the SCHAD 
enzyme. As a result, there is an accumulation of medium and 
short-chain fatty acids, which are not broken down properly, and 
therefore cannot enter the metabolic pathway leading to ATP 
production, which ultimately affects the KATP channel pathway. 
Other targets of HADH inactivity can effect G protein-coupled 
receptor GPR40 (97) as well play a role in the inhibition of car-
nitine palmitoyltransferase 1 (CPT-1) (98). HADH is known to 
be regulated by transcription factors such as FOXA2, which may 
play a role in the differentiation process of pancreatic β-cells in 
mice (99).
The clinical presentation of HADH–CHH is also a varied 
among patients with the disease. The patients are largely from 
consanguineous families, and the age of disease onset is unpre-
dictable, with cases presenting at birth with severe CHH, as well 
other late onset with mild hypoglycemia. The first case of adult 
HH due to a HADH mutation has been reported, where the 
hypoglycemia became milder as the patient grew older (100).
Abnormal levels of hydroxybutyryl-acylcarnitine in blood and 
3-hydroxyglutaric acid in urine are usually found in HADH–CHH 
patients. However, all cases have been known to be responsive to 
diazoxide, although patients may still suffer from a hypoglycemic 
episode after a protein-rich meal. Examples of HADH mutations 
include IVS6-2a > g. This is a splice site mutation generating, an 
enzyme which has ~90% reduction is activity in comparison to 
controls. The p.Met188Val mutant, however, had mild effects on 
enzyme activity, which originated in a patient with normal levels 
of acylcarnitines and organic acids.
It has been reported that some HADH–CHH patients are 
also leucine sensitive (101), however, unlike GLUD1–CHH 
patients, they do not present with hyperammonemia. The 
mechanism of leucine action in HADH–CHH patients is clearly 
different to GLUD1–CHH. A protein–protein interaction 
between SCHAD and GDH had been demonstrated in the liver 
(86). Furthermore, a hadh KO mouse model developed by Li 
et al. (86) had previously shown that leucine loading leads to a 
hyperinsulinemic response (86). With this in mind, the direct 
link between SCHAD and GDH in patient lymphoblast cells was 
first reported by Heslegrave et al. (101). It has been postulated 
that the regulation of the GDH enzyme may be affected by the 
ratio of active SCHAD to GDH in pancreatic β-cells. SCHAD 
may be an inhibitor of GDH, which suppresses the secretion of 
insulin via leucine stimulation (102). Loss of protein–protein 
interaction may cause a mild increase in activation of GDH 
(86). Patients with HADH mutations do have lower levels of 
SCHAD, although this is not the case in all patients, which may 
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be the cause of the varying phenotypes seen in these patients. 
Further studies are needed to understand the mechanism of this 
interaction.
HNF4A: Hepatocyte Nuclear Factor 4 
Alpha
The HNF4A gene belongs to the nuclear hormone receptor super-
family. This gene harbors two distinct promoter regions known as 
P1 and P2. The transcription of the latter promoter is enhanced 
in the pancreatic β-cells, where it regulates key genes involved in 
glucose-stimulated insulin secretion (103, 104). Genes known to 
be regulated by HNF4A include glucose transporter-2, glycolytic 
enzymes, and enzymes involved in mitochondrial metabolism 
(104). A gene of significant interest is KCNJ11, which is also regu-
lated by HNF4A. It has been hypothesized that HNF4A may down 
regulate the expression of the KCNJ11 by up to 60%, although the 
precise mechanism is not known (105). The decreased expres-
sion was observed in mice using the conditional Cre-loxP-based 
inactivation system, which was used to delete the HNF4A gene. 
However conflicting evidence has shown by other researchers 
where the deletion of HNF4A had no effect on the activity or 
expression of KCNJ11 (106, 107).
The peroxisome proliferator-activated receptor alpha (PPARα) 
is a transcription factor which may be an alternative target of 
HNF4A activity. PPARα is also involved in regulating the expres-
sion of enzymes involved in fatty acid oxidation, and during a 
fast PPARα, KO mice have been shown to develop HH (108). 
The association between the two transcription factors is based on 
the fact that there are reduced levels of PPARα in β-cells lacking 
HNF4A (105). Such a reduction of PPARα can lead to a reduc-
tion in the levels of β-oxidation, leading to the accumulation of 
lipids such as malonyl-CoA within the cytoplasm. This in turn 
can inhibit the enzyme CPT-1, which can raise the concentration 
of cytosolic long-chain acyl-CoA, terminating with the increased 
production of insulin.
Only a small fraction of patients with dominant inactivat-
ing HNF4A mutations actually go on to develop CHH (106, 
109–111), and hence the penetrance of the disease is quite low. 
However, these patient’s do go on to develop maturity onset dia-
betes type 1 (MODY1), a form diabetes which is inherited in an 
autosomal dominant fashion (106). Another prominent feature in 
HNF4A–CHH patients is macrosomia. In comparison to family 
members, the HNF4A–CHH patients had a median increase in 
birth weight by 790 g in one cohort (106) and 751 g in another 
(109). This increase in birth weight is similar to patients with KATP 
channel mutations.
HNF1A: Hepatocyte Nuclear Factor 1 
Alpha
The HNF1A gene codes for a transcription factor, which is known 
to enhance the expression of liver specific genes, as well as genes 
expressed in the pancreas (112). Heterozygous, loss of function 
mutations in this gene are known to cause CHH. HNF1A–CHH 
patients present with milder fetal macrosomia, and are known to 
develop MODY3 as they age. The severity of the CHH is also less 
compared to patients with HNF4A–CHH. It is currently unknown 
as to why there is switch from CHH to MODY3 in these patients. 
HNF1A–CHH patients are responsive to drugs such as diazoxide. 
For the first time, Rozenkova and colleagues have demonstrated 
the functional impact of HNF1A mutations, which cause CHH. 
DNA-binding studies revealed that the p.Asn62Lysfs*93 and 
p.Leu254Gln HNF1A mutations reduced the transcriptional 
activity of the protein by 2.9 and 22%, respectively (113). The 
overall incidence of HNF1A–CHH is very low, and this could 
be due to the fact that some patients escape detection as their 
phenotype is very mild.
SLC16A1: Solute Carrier Family 16, 
Member 1
The SLC16A1 gene encodes for a transporter protein known 
as monocarboxylate transporter 1 (MCT1). Its function is to 
regulate the movement of lactate and pyruvate into the pancre-
atic β-cell. Under normal physiological conditions, lactate and 
pyruvate are present in low concentrations in the β-cell as they 
are potent insulin secretagogues. This transporter protein is 
not normally expressed (disinhibited) in pancreatic β-cells, but 
gain-of-function mutations in the promoter region of the gene 
enable its expression in β-cells, this allowing increased  pyruvate 
into the β-cell and eventually leading to CHH. A unique feature 
about these patients is that the onset of the disease is exercise 
induced. Hypoglycemia was observed in these patients after 
around 30–45  min of strenuous exercise. These features were 
prominent in Finnish cohort of 13 patients (114). In these 
patients, lactate is produced during anaerobic exercise, and 
this is fed into the Krebs cycle together with pyruvate, which 
 generates ATP and triggers insulin release through the KATP 
channel pathway. Most patients are responsive to medical 
management using diazoxide, although this is ineffective after 
anaerobic exercise, hence strenuous exercise is not tolerated by 
these patients (115).
UCP2: Uncoupling Protein 2
The UCP2 gene codes for a mitochondrial carrier protein largely 
expressed in both pancreatic α- and β-cells. The structure of the 
UCP2 protein entails six transmembrane domains (116) and one 
nucleotide-binding domain. It has been hypothesized that this 
gene provides protection against oxidative stress during fatty 
acid metabolism. In vivo studies observing UCP2 KO mice have 
shown that these mice develop hyperinsulinism, which suggests 
that UCP2 is involved in the regulation of insulin secretion. In 
animal models, it has also been shown that the overexpression 
of ucp2 can cause diabetes. Hence there is a clear involvement of 
UCP2 in glucose physiology. It has been hypothesized that the 
UCP2 protein may be involved in regulating the leak of protons 
across the inner mitochondrial membrane (117). This would 
lead to the uncoupling of mitochondrial oxidative metabolism 
from ATP synthesis, which ultimately reduces the ATP yield for 
substrate oxidation.
González-Barroso et  al. (118) described the first two cases 
of CHH due to mutations in the UCP2 gene (118). The age of 
presentation in these two patients was later around ~8 months. 
Insulinoma and yeast cells have been used to further understand 
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the link between UCP2 and HH. Studies have revealed that 
mutations in UCP2 have a loss-of-function effect on the protein, 
which enhances insulin secretion, whereas the wild type (WT) 
UCP2 protein inhibits insulin secretion (118). Further studies 
are warranted in order to establish a clear mechanism of UCP2-
induced HH.
insulin Receptor Gene Mutation
A report of a novel heterozygous mutation in the insulin recep-
tor gene has been causative of hypoglycemia in patients with 
severe HH (119). The autosomal dominant change in the insulin 
receptor gene (p.Arg1174Gln) has been described to cause post-
prandial hyperinsulinemic hypoglycemia (PPHH) (119). PPHH 
occurs after a few hours of eating a meal. PPHH is secondary to 
the unregulated insulin release due to the meal ingested.
The hyperinsulinism seen in these patients appear to be due to 
a reduction in the clearance of insulin rather than the increased 
release of insulin, since C-peptide concentrations are within 
normal ranges.
NON-GeNeTiC CAUSeS OF HH
Postprandial Hyperinsulinemic 
Hypoglycemia
Other non-genetic causes of PPHH also exist (Table 1):
Dumping Syndrome
Dumping syndrome is an example of PPHH, which occurs after 
Nissen’s fundoplication (120). Ingestion of carbohydrate-rich 
foods is absorbed into the small intestine, which in turn cause 
increased glucose absorption, hyperglycemia, rapid release of 
insulin, and overall results in hypoglycemia. The molecular 
mechanisms of this is thought to be due to abnormally exagger-
ated levels of glucagon-like peptide-1 (GLP-1), which is known 
to contribute to the HH (121).
Where dumping syndrome is suspected, a mixed meal or oral 
glucose tolerance test (OGTT) is performed. A current diagnos-
tic criteria for dumping syndrome is a decrease of more than 
6 mmol/L between peak and nadir blood glucose levels (122).
insulin Autoimmune Syndrome
Insulin autoimmune syndrome is also known as Hirata disease, 
which is a rare cause of hypoglycemia characterized by high levels 
of endogenous insulin autoantibodies. This condition has the 
absence of pathological islets and is in the absence of exposure 
to exogenous insulin (123). Insulin autoimmunity affects mainly 
adults of 40 years and over.
In this condition, post meal or after a glucose load, the raised 
blood glucose levels cause insulin secretion but hyperglycemia 
occurs. This is due to the insulin antibodies binding to insulin and 
reducing the bioavailability to its receptor and this in turn leads 
to a reduction in its action. After a few hours, the blood glucose 
levels decrease with corresponding insulin concentrations, and 
the bound insulin is released from the antibodies, resulting in the 
hypoglycemia (124).
Bariatric Surgery
Obese individuals with comorbidities such a type-2 diabetes 
mellitus are causing a rise in invasive gastric bypass procedures 
(125). Prior to weight-loss, these patients have shown a resolution 
of their hyperglycemia. The theory for this mechanism is that 
the food bypasses the upper gastrointestinal tract and is passed 
along to the lower gut, here the insulinotropic hormone; GLP-1 
is hyperstimulated (126). However, a serious side effect appears 
to be an increase in gastric bypass patients presenting with PPHH 
and nesidioblastosis (127).
Non-insulinoma Pancreatogenous 
Hypoglycemia Syndrome
Postprandial neuroglycopenia characterizes the non-insulinoma 
pancreatogenous hypoglycemia syndrome (NIPHS) (128). The 
genetic cause of NIPHS remains to be found, these patients are 
negative for prolonged fasts and show islet hypertrophy and evi-
dence of nesidioblastosis in the absence of insulinoma. However, 
studies are yet to identify if the increased β-cell proliferation pro-
duction as well as pancreatic differentiation factors are contribut-
ing agents (129). In the absence of KATP channel mutations, some 
of these patients are surprisingly responsive to diazoxide (130), 
while the unresponsive patients require a partial pancreatectomy.
insulinoma
In adults, insulinomas are the most common cause of endogenous 
HH with an incidence of four per million (131). Predominantly 
of benign origin, these pancreatic tumors secrete insulin and are 
usually small and <2 mm in diameter. Initially, hypoglycemia was 
thought to show only either on fasting or post-exercise; however, 
it has also presented post meal (132). In suspected cases, cur-
rent guidelines recommend the measurement of plasma glucose, 
insulin, C-peptide, proinsulin, β-hydroxybutyrate, insulin 
antibodies, and circulating oral hypoglycemic agents during the 
hypoglycemic episode (133).
CONCLUSiON
Hyperinsulinemic hypoglycemia is characterized by the dys-
regulation of insulin secretion from pancreatic β-cells. The most 
severe forms of congenital hyperinsulinemic hypoglycemia 
are due to molecular defects in the genes ABCC8 and KCNJ11. 
Milder forms of hyperinsulinemic hypoglycemia may occur due 
to molecular defects in several other genes, which play a key role 
in the regulation of insulin secretion. Currently genetic abnor-
malities are only found in about 50% of patients presenting with 
hyperinsulinemic hypoglycemia. Understanding the molecular 
mechanisms of dysregulated insulin secretion in those patients 
with no genetic etiology will provide novel insights into pancre-
atic β-cell function.
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